地舒单抗长期持续用药的真实世界数据:奥地利骨质疏松门诊回顾性分析
该回顾性分析评估绝经后骨质疏松女性在地舒单抗治疗中的长期持续用药情况。持续用药与骨密度升高、CTX降低相关,且不良事件和严重不良事件较少。
要点
- 851例患者中71%在7.5年随访时仍持续使用地舒单抗。
- 持续用药与骨密度升高、CTX降低及不良事件较少相关。
核心结论
- 这是首个显示地舒单抗长期(>3年)真实世界持续用药可在多数患者中维持高水平(>70%)的研究。
- 地舒单抗耐受性良好,并与CTX水平降低和骨密度升高相关。
研究设计与样本
- 回顾性数据分析,纳入奥地利骨质疏松门诊(AOC)851例接受地舒单抗治疗的绝经后骨质疏松女性。
- 持续用药按每6个月间隔(+/-8周)按时接受地舒单抗的患者数量和比率确定。
- 总人群分为内部患者(在AOC注射和监测,74%)和外部患者(在执业医师处注射、偶尔在AOC监测,26%)。
- 内部患者在固定时间点评估疗效参数(骨密度和骨标志物CTX)及耐受/安全性参数(副作用、不良事件、严重不良事件)。
主要发现
- 851例患者中71%(内部患者73%、外部患者64%)在7.5年随访时仍持续用药。
- 骨密度升高和CTX降低在总体及配对比较中均有统计学意义(所有p < .001)。
- 持续用药患者的不良事件和严重不良事件低于非持续用药患者,但副作用无此差异。
临床怎么用
- 真实世界中长期使用地舒单抗的持续用药率可维持在较高水平,支持其在绝经后骨质疏松中的长期应用。
- 持续用药与骨密度升高和CTX降低相关,提示坚持治疗对疗效的重要性。
局限性
- 为回顾性数据分析,可能存在选择偏倚和信息偏倚。
- 内部患者与外部患者的监测方式不同,可能影响持续用药的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In short-term studies, persistence with denosumab has been higher than with other osteoporosis drugs. This study shows that persistence can be maintained in the long-term and is associated with efficacy and safety parameters. PURPOSE: To assess long-term persistence with denosumab in postmenopausal women with osteoporosis. Secondary purposes were the evaluation of changes in efficacy and tolerance/safety parameters over time. METHODS: Persistence was determined by number and rate of patients receiving denosumab on time in 6-month intervals (+ / - 8 weeks). The total population was stratified by internal patients (injections and monitoring at the Austrian Osteoporosis Clinic [AOC], 74%) and external patients (injections at the practitioner's office with occasional monitoring at the AOC, 26%). In internal patients, efficacy parameters including bone mineral density (BMD) and the bone marker CTX were assessed at fixed time points and tolerance/safety parameters including side effects (SEs), adverse events (AEs), and serious AEs (SAEs) evaluated. RESULTS: Of 851 patients, 71% (73% internal and 64% external) were persistent at 7.5 years of follow-up. The mean rate of cumulative persistence in internal patients decreased from 94% at the time of the second dose to 73% at the time of the fifteenth dose. BMD increased and CTX decreased, overall and in pairwise comparisons (all p < .001). AEs and SAEs, but not SEs, were lower in persistent than non-persistent patients. CONCLUSIONS: This is the first study showing that long-term (> 3 years) real-world persistence with denosumab could be maintained at a high level (> 70%) in most patients. Denosumab was well tolerated and associated with decreased CTX levels and increased BMD.
引用
- Boschitsch E, Naegele O, Klinger A, et al. Long-term persistence with denosumab: real-world data from the Austrian Osteoporosis Clinic (AOC). A retrospective data analysis. Osteoporos Int. 2021. PMID: 34432114. doi:10.1007/s00198-021-06102-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。